title: Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: Differences in presentation and outcome in the AVID registry.
abstract: BACKGROUND
  The etiology of structural heart disease in patients with life-threatening arrhythmias (ventricular tachycardia [VT]/ventricular fibrillation [VF]) may define clinical characteristics at presentation, may require that different therapies be administered, and may cause different mortality outcomes.
  
  
  METHODS
  In the Antiarrhythmics Versus Implantable Defibrillators (AVID) registry, baseline clinical characteristics, treatments instituted, and ultimate mortality outcomes from the National Death Index were obtained on 3117 patients seen at participating institutions with VT/VF, irrespective of participation in the randomized trial. By use of these data, 2268 patients with coronary artery disease (CAD) were compared with 334 patients with dilated nonischemic cardiomyopathy (DCM).
  
  
  RESULTS
  The CAD group was 7 years older and had a higher percentage of males. DCM patients were more likely to be African American, have severely compromised left ventricular function (52% vs 39%), and have a history of congestive heart failure symptoms (62% vs 44%). Patients with CAD were more likely to be treated with b-blockers and calcium channel blockers and less likely to be treated with angiotensin-converting enzyme inhibitors. Patients with DCM were more likely to be treated with diuretics, warfarin, and an implantable cardioverter defibrillator for VT/VF (54% vs 48% for CAD); the use of other antiarrhythmic therapies did not differ between the 2 groups. Two-year survival was not significantly different between the groups (76.6% [95% CI 74.6%-78.7%] vs 78.2% [95% CI 73.6%-82.9%]).
  
  
  CONCLUSIONS
  In AVID registry patients with VT/VF, demographic and clinical characteristics were different between patients with CAD and those with DCM. Despite these differences, overall survival was similar in these 2 groups.
authors.affiliation: St Luke's-Roosevelt Hospital Center, New York, NY 10019, USA. fehlert@slrhc.org
authors.forename: F A
authors.initials: FA
authors.lastname: Ehlert
authors.forename: D S
authors.initials: DS
authors.lastname: Cannom
authors.forename: E G
authors.initials: EG
authors.lastname: Renfroe
authors.forename: H L
authors.initials: HL
authors.lastname: Greene
authors.forename: R
authors.initials: R
authors.lastname: Ledingham
authors.forename: L B
authors.initials: LB
authors.lastname: Mitchell
authors.forename: J L
authors.initials: JL
authors.lastname: Anderson
authors.forename: B D
authors.initials: BD
authors.lastname: Halperin
authors.forename: J M
authors.initials: JM
authors.lastname: Herre
authors.forename: R M
authors.initials: RM
authors.lastname: Luceri
authors.forename: R A
authors.initials: RA
authors.lastname: Marinchak
authors.forename: J S
authors.initials: JS
authors.lastname: Steinberg
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000401:mortality* / Q000628:therapy; D003327:Coronary Disease / Q000188:drug therapy / Q000401:mortality* / Q000628:therapy; D017147:Defibrillators, Implantable; D006801:Humans; D012042:Registries; D017180:Tachycardia, Ventricular / Q000188:drug therapy / Q000401:mortality* / Q000628:therapy; D014693:Ventricular Fibrillation / Q000188:drug therapy / Q000401:mortality* / Q000628:therapy
chemical_list: D000889:Anti-Arrhythmia Agents